PURPOSE: There is accumulating evidence that galanin receptors (GALRs) may be tumor suppressors in head and neck squamous cell carcinoma (HNSCC). Promoter methylation status and gene expression were assessed in a large panel of primary tumors, based on the hypothesis that CpG hypermethylation might silence the galanin gene. EXPERIMENTAL DESIGN: Galanin expression was examined using reverse transcription-polymerase chain reaction (PCR). The methylation status of the galanin promoter was studied using bisulfate sequencing and methylation-specific PCR. UM-SCC-54 was stably transfected to express galanin. RESULTS: Galanin expression was absent in 3/12 (25.0%) UM-SCC cell lines, whereas three nonmalignant cell lines had stable expression. Galanin methylation was found in 24/100 (24.0%) cases. HNSCC tumor specimens was significantly correlated with the GALR1 methylation status (P = 1.88E-06). The presence of galanin promoter hypermethylation was statistically correlated with a decrease in disease-free survival (log-rank test, P = 6.02E-05). A multivariate logistic regression analysis showed that methylation of galanin and methylation of the gene pair galanin and GALR1 had an odds ratio for recurrence of 8.95 [95% confidence interval (CI), 2.29-35.03] and 23.84 (95% CI, 2.74-207.17), respectively. UM-SCC-54 cells that are GALR1-proficient but have hypermethylated galanin exhibited suppressed cell proliferation following exogenous expression of galanin. CONCLUSIONS: Association of frequent promoter hypermethylation and gene silencing with poor survival, combined with growth suppression of HNSCC cells after forced gene expression, supports the hypothesis that galanin acts as a tumor suppressor. These data suggest that galanin and GALR1 are potential therapeutic targets and prognostic factors.
PURPOSE: There is accumulating evidence that galanin receptors (GALRs) may be tumor suppressors in head and neck squamous cell carcinoma (HNSCC). Promoter methylation status and gene expression were assessed in a large panel of primary tumors, based on the hypothesis that CpG hypermethylation might silence the galanin gene. EXPERIMENTAL DESIGN: Galanin expression was examined using reverse transcription-polymerase chain reaction (PCR). The methylation status of the galanin promoter was studied using bisulfate sequencing and methylation-specific PCR. UM-SCC-54 was stably transfected to express galanin. RESULTS: Galanin expression was absent in 3/12 (25.0%) UM-SCC cell lines, whereas three nonmalignant cell lines had stable expression. Galanin methylation was found in 24/100 (24.0%) cases. HNSCC tumor specimens was significantly correlated with the GALR1 methylation status (P = 1.88E-06). The presence of galanin promoter hypermethylation was statistically correlated with a decrease in disease-free survival (log-rank test, P = 6.02E-05). A multivariate logistic regression analysis showed that methylation of galanin and methylation of the gene pair galanin and GALR1 had an odds ratio for recurrence of 8.95 [95% confidence interval (CI), 2.29-35.03] and 23.84 (95% CI, 2.74-207.17), respectively. UM-SCC-54 cells that are GALR1-proficient but have hypermethylated galanin exhibited suppressed cell proliferation following exogenous expression of galanin. CONCLUSIONS: Association of frequent promoter hypermethylation and gene silencing with poor survival, combined with growth suppression of HNSCC cells after forced gene expression, supports the hypothesis that galanin acts as a tumor suppressor. These data suggest that galanin and GALR1 are potential therapeutic targets and prognostic factors.
Authors: S Takebayashi; T Ogawa; K Y Jung; A Muallem; H Mineta; S G Fisher; R Grenman; T E Carey Journal: Cancer Res Date: 2000-07-01 Impact factor: 12.701
Authors: Tamotsu Kuroki; Francesco Trapasso; Sai Yendamuri; Ayumi Matsuyama; Hansjuerg Alder; Masaki Mori; Carlo M Croce Journal: Cancer Res Date: 2003-07-01 Impact factor: 12.701
Authors: T Bartfai; U Langel; K Bedecs; S Andell; T Land; S Gregersen; B Ahrén; P Girotti; S Consolo; R Corwin Journal: Proc Natl Acad Sci U S A Date: 1993-12-01 Impact factor: 11.205
Authors: Malcolm V Brock; Craig M Hooker; Emi Ota-Machida; Yu Han; Mingzhou Guo; Stephen Ames; Sabine Glöckner; Steven Piantadosi; Edward Gabrielson; Genevieve Pridham; Kristen Pelosky; Steven A Belinsky; Stephen C Yang; Stephen B Baylin; James G Herman Journal: N Engl J Med Date: 2008-03-13 Impact factor: 91.245
Authors: Hannah Lui Park; Myoung Sook Kim; Keishi Yamashita; William Westra; Andre Lopes Carvalho; Juna Lee; Wei-Wen Jiang; Jin Hyen Baek; Junwei Liu; Motonobu Osada; Chul-So Moon; Joseph A Califano; Masaki Mori; David Sidransky Journal: Int J Cancer Date: 2008-06-01 Impact factor: 7.396
Authors: Rajat Banerjee; Elizabeth A Van Tubergen; Christina S Scanlon; Robert Vander Broek; Joel P Lints; Min Liu; Nickole Russo; Ronald C Inglehart; Yugang Wang; Peter J Polverini; Keith L Kirkwood; Nisha J D'Silva Journal: Mol Cancer Ther Date: 2014-02-25 Impact factor: 6.261
Authors: Fernanda Visioli; Yugang Wang; Goleeta N Alam; Yu Ning; Pantelis V Rados; Jacques E Nör; Peter J Polverini Journal: PLoS One Date: 2014-06-25 Impact factor: 3.240